BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2
Completed
- Conditions
- Diffuse, Large B-Cell, Lymphoma
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 67
- Registration Number
- NCT02391116
Roniciclib Mass Balance Study
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT02390154
- Locations
- 🇭🇺
PRA Magyarorszag Kft. Fazis I-es Klin.Farmakol. Vizsgalohely, Budapest, Hungary
BAY1238097, First in Man
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT02369029
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT02368951
Phase III Copanlisib in Rituximab-refractory iNHL
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT02369016
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT02367027
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Phase 3
Completed
- Conditions
- Lymphoma,Non-Hodgkin
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 458
- Registration Number
- NCT02367040
- Locations
- 🇺🇸
MSK Bergen, New Jersey, New Jersey, United States
🇺🇸MSK Monmoth, New Jersey, New Jersey, United States
🇺🇸MSK Westchester, Harrison, New York, United States
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 75
- Registration Number
- NCT02366949
Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: BAY 1841788(ODM-201)
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT02363855
JAYDESS Drug Utilization Study in Sweden
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10000
- Registration Number
- NCT02349815
- Locations
- 🇸🇪
Many Locations, Multiple Locations, Sweden
© Copyright 2025. All Rights Reserved by MedPath